Splice Bio is a biotechnology company based in Barcelona, Spain. The company was founded in 2020 by Miquel Vila-Perelló and Silvia Frutos, who are both experts in protein chemistry and biotechnology. Splice Bio is developing a new gene therapy platform that uses inteins, which are natural proteins that can be used to splice DNA. This platform has the potential to deliver larger genes to cells, which could make it possible to treat a wider range of genetic diseases.

In 2022, Splice Bio raised €50 million in Series A funding. The funding was led by UCB Ventures and Ysios Capital, with participation from New Enterprise Associates (NEA), Gilde Healthcare, and Novartis Venture Fund. The company plans to use the funding to advance its gene therapy platform and develop its pipeline of potential therapies.
Splice Bio is one of a number of companies that are developing new gene therapy platforms. These platforms have the potential to revolutionize the treatment of genetic diseases, which are currently difficult or impossible to treat. Splice Bio is well-positioned to succeed in this space, as it has a strong team of experienced scientists and a promising technology.

Here are some additional details about Splice Bio:
Headquarters: Barcelona, Spain
Founded: 2020
Founders: Miquel Vila-Perelló and Silvia Frutos
CEO: Miquel Vila-Perelló
CTO: Silvia Frutos
Funding: €50 million (Series A)
Investors: UCB Ventures, Ysios Capital, New Enterprise Associates (NEA), Gilde Healthcare, Novartis Venture Fund
Technology: Protein splicing platform using inteins
Pipeline: Potential therapies for a range of genetic diseases